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Identifying the Carotid ‘High Risk’ Plaque: Is it Still a
Riddle Wrapped up in an Enigma?
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The selection of patients for many vascular interventions has largely been based on the severity of luminal narrowing.
However, histological data from the coronary and carotid circulations suggest that other plaque features such as inflam-
mation and fibrous cap thickness may be more important in predicting future thrombo-embolic events.
This paper reviews the available evidence for identifying carotid atheroma at high risk of being associated with clinical
events. Despite a large number of imaging and biomarker studies, ‘presenting symptoms’ remains the most clearly
identified risk predictor for ischaemic stroke in patients with carotid stenosis. At present, no imaging modality or plasma
biomarker has clearly identified a high risk sub-group of asymptomatic carotid stenoses for which the benefit of carotid
intervention is comparable to that of symptomatic atherosclerosis.
Emerging developments in MRI, transcranial Doppler and scintigraphic imaging hold some promise for the future.
However, the multiple mechanisms and sites determining ischaemic stroke occurrence in association with atherosclerosis
suggests that systemic therapies are likely to be the most powerful modality in the management of asymptomatic disease.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Atherosclerosis is a common systemic problem with
multiple arterial sites affected. Some degree of carotid
artery narrowing has been reported in up to 75% of
men and 62% of women aged 65 years.1 At present
the selection of patients for carotid revascularisation
is, to a large extent, determined by the severity of
arterial narrowing.
Approximately 5% of subjects aged 65 years have
a 50e99% stenosis.1e3 Despite evidence from a num-
ber of randomised controlled trials demonstrating the
benefit of carotid endarterectomy (CEA) over medical
therapy, there remains controversy over patient selec-
tion.2e8 This controversy primarily relates to the
management of asymptomatic carotid artery disease.
While two randomised trials have demonstrated
that CEA reduces the long-term stroke risk, the abso-
lute risk reduction is only approximately 1% per
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subjects who have an asymptomatic carotid stenosis
and the loss of benefit resulting from a small increase
in perioperative complications commonly reported in
other prospective studies, continues to engender con-
cern about patient selection.9
Randomised trials of coronary stenting suggest that
revascularisation of stable stenoses or occlusions
confers no additional benefit over intensive medical
therapy alone.10 Hence the identification of athero-
sclerotic plaques which confer excess risk of events
is fundamental to the selection of patients for vascular
intervention. In this review we discuss the concept of
the high risk plaque and its identification as relevant
to the management of carotid atherosclerosis. The
definition of ‘high risk’ in the context of this review is
its association with ischaemic stroke and not surgery.
Pathobiology
There are many mechanisms that determine when/
how an ischaemic stroke will occur and all arebehalf of European Society for Vascular Surgery.
3High Risk Carotid Plaquedifficult to predict precisely (Fig. 1). Ischaemic
strokes result from thrombo-embolism arising from
an array of sites including the heart, aortic arch,
carotid, vertebro-basilar system and intra-cranial
arteries. Intra-cardiac thrombus is promoted by im-
paired chamber contractility and stasis and rando-
mised trials have demonstrated a reduced stroke
incidence in patients with persistent atrial fibrillation
treated with warfarin.11 Studies of the coronary circu-
lation and, to a lesser degree the carotid system, have
suggested that arterial thrombo-embolic events result
from rupture or erosion of the fibrous cap overlying
an advanced atherosclerotic plaque.12e14 A number of
morphologic features have been associatedwith plaque
rupture, including a thin fibrous cap, accumulation of
macrophages within the cap, reduced numbers of ma-
trix producing vascular smoothmuscle cells and a large
lipid filled core.12 A summation analysis of small stud-
ies comparing carotid atheroma removed from severe
symptomatic and asymptomatic stenoses observed
that neurological events were significantly associated
with plaque rupture, fibrous cap thinning and infiltra-
tion by macrophages and Tcells.13 However, highlight-
ing the unpredictable nature of this problem, plaque
rupture was only present in 48% of plaques removed
from recently symptomatic patients.13 In the largest
histology study of carotid atheroma, Redgrave et al.
reported a good correlation between plaqueinflammation/cap rupture with time since stroke
onset.14However, therewas little evidence of a relation-
ship between inflammation/cap rupture and time since
TIA onset.14 Quite why there should be such a differ-
ence between TIA and stroke patients has not been
clarified.
Most published studies (to-date) are limited by the
fact that many of the operations were performed
months after the index clinical event and therefore
pathological findings may not always reflect those
that were present at the time of onset of symp-
toms.13,14 Accordingly, it is possible that inflammation
could follow rather than precede plaque rupture.
When and where plaque rupture will occur is also
influenced by the wall stress generated. This is depen-
dent upon plaque site, blood pressure and physical
features of the arterial wall such as rigidity.12
The lipid core contains high concentrations of
tissue factor and can promote thrombus development
following exposure to flowing blood following cap
rupture.12 The degree of thrombus formation is
influenced by the pro-coagulant and anti-coagulant
balance within the exposed lipid core and the sys-
temic circulation. This balance, combined with the
blood flow characteristics at the arterial site in
question, will influence whether an occlusive or
non-occlusive thrombosis occurs. These factors will
also influence the potential for distal embolisationFig. 1. Mechanisms important in the development of ischaemic stroke. TF ¼ Tissue factor; TFPI ¼ Tissue factor pathway
inhibitor.Eur J Vasc Endovasc Surg Vol 35, January 2008
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proximal occlusion or distal embolisation will then
depend on many factors including the site of distal
embolisation, the anatomy of the circle of Willis, the
status of the contralateral carotid artery and vertebro-
basilar system and the ability of the brain area to with-
stand ischaemia (Fig. 1).
Clinical Presentation and Severity of Carotid
Stenosis in Identifying High Risk Carotid
Atheroma
At the present time, the most powerful predictor of
‘high risk’ carotid atherosclerosis is the presence of
recent focal neurological symptoms ipsilateral to a ca-
rotid stenosis.2e6,15 Table 1 illustrates the incidence of
ipsilateral stroke in patients allocated ‘best medical
treatment’ in four randomised trials of CEA for symp-
tomatic or asymptomatic disease.2e6 These data
(Table 1) illustrate a number of important features
regarding carotid atherosclerosis. Following a stroke,
transient ischaemic attack (TIA) or retinal infarction
(in association with a 80e99% carotid stenosis), one
quarter of patients treated medically will experience
a stroke over the next three years. In a cohort of pa-
tients with similarly severe carotid stenoses (but no
symptoms), the incidence of stroke is only about 6%
at three years. The risk of stroke associated with an
asymptomatic carotid stenosis remains about 2% per
year, in contrast to the acute risk which accompanies
a symptomatic stenosis.3,4
The ‘very early’ risk associated with a symptomatic
stenosis is probably even greater than that detailed in
Table 1. This is because the European and North
American trials enrolled patients who had experi-
enced a neurological event within 6 months.4,5 Recent
population studies suggest that up to 32% of patients
with 50% carotid stenoses will suffer a stroke within
12 weeks of the index event and prior to carotid inter-
vention.16 The vital importance of symptoms in the
identification of high risk carotid atherosclerosis isEur J Vasc Endovasc Surg Vol 35, January 2008illustrated by a pooled analysis of the endarterectomy
trials.17 If surgery is carried out within 2 weeks of
symptoms, only 5 patients with 50% stenoses re-
quire surgery in order to prevent one stroke. How-
ever, if surgery is delayed for >12 weeks, 125
patients with 50% stenoses have to undergo surgery
to prevent one stroke. There are other important clin-
ical parameters that determine stroke risk,17,18 includ-
ing older age, hypertension, discriminating clinical
symptomatology (unilateral weakness as opposed to
ocular events, duration 60 minutes) and diabetes.18
Accordingly, there is already excellent data to select
patients with high risk symptomatic stenoses most
likely to benefit from carotid intervention.
Conversely, the situation with regard to asymptom-
atic stenoses is in marked contrast, with relatively
little evidence of a clear ‘high risk’ sub-group. The
benefit conferred by CEA for asymptomatic disease
does appear to be more apparent in men,2,8 although
this gender disparity could partly reflect worse proce-
dural outcomes in women, rather than a greater risk of
events during medical therapy.2,8 The MRC Asymp-
tomatic Carotid Surgery Trial (ACST) also identified
a lack of efficacy of carotid surgery in patients aged
75 years. This was not due to an increased proce-
dural risk but, rather, a limited life expectancy.3
Issues in Identifying ‘High Risk’ Sub-group of
Patients with Asymptomatic Carotid Stenosis
As outlined above, the identification of a ‘high risk for
stroke’ sub-group in patients with recent symptoms is
feasible utilising nothing more than clinical presenta-
tion and stenosis severity. The same situation does not
apply in the management of the great majority of pa-
tients who have asymptomatic carotid disease. This
has led to marked global disparities in managing
these patients.
There are several reasons why it has not been pos-
sible to predict the behaviour of carotid atheroma in
asymptomatic patients.Table 1. Relationship between symptoms, stenosis severity and stroke risk on medical therapy
NASCET ECST ACAS ACST
Stenosis n time stroke stenosis n time stroke stenosis n time stroke stenosis n time stroke
<50% 690 60 19%
50e69% 428 60 22% 60e69% 137 36 11% 60e69% 131 36 6% 60e79% 642 60 10%
70e79% 43 24 21% 70e79% 170 36 9% 70e79% 94 36 5% 80e99% 918 60 10%
80e89% 33 24 27% 80e89% 159 36 21%
90e99% 24 24 35% 90e99% 60 36 32%
80e99% 57 24 31% 80e99% 219 36 24% 80e99% 88 36 3%
NASCET¼North American symptomatic carotid endarterectomy trial,4 ECST¼ European carotid surgery trial,5 ACAS¼Asymptomatic
carotid atherosclerosis study,2 ACST¼Asymptomatic carotid surgery trial.3 Stenosis severity was measured differently in each trial.
ACAS and ACST used ultrasound based criteria.2,3 NASCET and ECST used angiographic criteria but different measurements methods.4,5
5High Risk Carotid Plaque1) Plaque rupture may remain an ‘asymptomatic’
phenomenon, either because systemic anti-coagu-
lant factors minimise thrombus development or
because thrombus embolises to a ‘clinically silent’
area of the brain.
2) Multiple atheromatous plaques are commonly
present in combination. Studies in the coronary cir-
culation have demonstrated that patients often
have more than one ruptured plaque in the artery
supplying an infarcted myocardium, although
usually only one site has evidence of thrombosis.19
Accordingly, any technique for identifying rupture
prone plaque may have difficulty in identifying the
most clinically important anatomical lesion.
3) There is evidence of a systemic inflammatory re-
sponse in association with unstable plaques at mul-
tiple sites.20,21
4) Any plaque features that are to be useful in identi-
fying patients at high risk of stroke must be present
for a sufficient time period before the neurological
event occurs in order to permit detection and treat-
ment. Some of the pathological features linked with
symptomatic plaques (macrophage accumulation
and proteolytic enzyme release) are likely to be
present only shortly before fibrous cap rupture.
Imaging Methods for Identifying High
Risk Plaques
An array of imaging modalities (Table 2) have been
evaluated in the hope that they might reliably (and
accurately) identify features associated with plaque
rupture.19,22
Ultrasound has been subject to more scrutiny than
any other technique, primarily because of its portabil-
ity, availability and non-invasiveness, together with
the fact that it is the commonest means of determin-
ing stenosis severity in contemporary clinical prac-
tice. A number of subjective carotid plaque criteria
(eg grades of echolucency/echogenicity, surface irreg-
ularity) were initially assessed as being potentialpredictors of increased risk of suffering a stroke.
More recently, computer assisted measurement of
the gray scale median (GSM) and integrated backscat-
ter has enabled more reproducible assessment of
carotid plaques.20,21,23,24 A number of studies have
related carotid plaque echolucency to symptoms in
cross sectional comparisons with asymptomatic pa-
tients.23 Prospective studies examining the association
of plaque echogenicity and stroke have been limited.24
Gronholt and colleagues monitored 246 patients (135
symptomatic and 111 asymptomatic) with 50%
carotid stenosis over a mean of 4.4 years and demon-
strated an association between plaques with echolu-
cency above median and subsequent ipsilateral
stroke in previously symptomatic patients.24 The
investigators demonstrated no association between
plaque echolucency and outcome in asymptomatic
patients. Similarly, an evaluation of plaque echolu-
cency did not identify a sub-group in which carotid
endarterectomy was more beneficial in the ACST, al-
though details regarding the assessment technique
were not provided.3
The Asymptomatic Carotid Stenosis and Risk of
Stroke (ACSRS) study has recently reported on the in-
cidence of ipsilateral stroke in 1115 patients with an
asymptomatic carotid stenosis during a mean follow-
up of 37 months.25 The investigators used image nor-
malisation in order to improve the reproducibility of
grading of plaque echogenicity. In this study, patients
with a 70e99% stenosis and an echogenic plaque, had
a 7-year cumulative risk of stroke of 1%. This compares
with a 14% risk of stroke at 7 years in patients with
echolucent plaques.25 Further data incorporating auto-
mated gray scale median assessment is expected from
ACRS in due course and corroborative data from sim-
ilar studies is required prior to concluding that plaque
echogenicity can be definitively used to select patients
for carotid intervention.25
Interestingly a number of studies have also associ-
ated carotid plaque echolucency to an increased risk
of atherothrombotic events in unrelated vascular ar-
teries such as myocardial infarction or contralateralTable 2. Imaging methods of potential value in identifying high risk plaques
Technique High risk features Advantages Disadvantages
Angiography Stenosis severity; ulcer Available in most centres Only lumen visualised, invasive, stroke risk,
contrast related complications, radiation required
CT Calcification32 Rapid, readily available contrast related complications, radiation required
MRI (high
resolution)
Thin cap, cap rupture,
intra-plaque haemorrhage,
necrotic core28e31
Non-invasive, able to visualise wall
and lumen, less operator dependant
than ultrasound
Time required for acquisition, reconstruction and
analysis, exclusion of metal implants, availability
Ultrasound Echolucency, ulcer20e24 Non-invasive, able to visualise wall
and lumen.
Operator dependent
TCD Micro embolic signals33e37 Non-invasive, theoretically a very
direct measure of plaque instability
Very labour intensive, complex analysis,
prolonged assessment requiredEur J Vasc Endovasc Surg Vol 35, January 2008
6 J. Golledge and D.-A. Siewstroke.26,27 The latter findings support the concept of
a systemic destabilizing process which promotes mul-
tiple at risk plaques to become unstable.20,21
MRI and CTare increasingly being used to evaluate
carotid plaque instability.28e32 MRI features of plaque
instability, including a thin fibrous cap, a large ne-
crotic core and marked intraplaque haemorrhage,
have been associated with an increased risk of late,
ipsilateral ischemic events in asymptomatic patients,
although the majority of observed events were
TIAs.29 A more recent study found that intraplaque
haemorrhage (detected by MRI) was highly predictive
of recurrent ipsilateral ischaemic events. Interestingly,
this association was only observed in patients who
had previously been symptomatic. MR evidence of
intraplaque haemorrhage in the contralateral asymp-
tomatic carotid artery was not associated with an
increased long term risk of ischaemic stroke.30
Recent advances in MRI to reduce acquisition
times, while allowing for movement suggest that
this modality may provide the most detailed informa-
tion about carotid plaque composition.31 Further stud-
ies are required to assess whether this information
will be useful in identifying high risk asymptomatic
stenoses most likely to benefit from treatment with
surgery or angioplasty.
Transcranial Doppler (TCD) is the only method ca-
pable of diagnosing micro-embolic signals (MES) in
the intracranial arteries33 and the frequency of MES
detected in the ipsilateral middle cerebral artery has
been associated with an increased risk of cerebral
events in patients with symptomatic carotid steno-
ses.34 The detection of MES is also a potentially useful
measure of the efficacy of interventions such as med-
ication or surgery.35
In a small study of 42 asymptomatic patients, the de-
tection of MESwas associated with an increased risk of
stroke and TIA (in combination) during follow-up.36
More recently, Abbott and colleagues studied 202 sub-
jectswith asymptomatic 60e99%carotid stenoses every
6 months with TCD for 60 minutes.37 By Kaplan-Meier
analysis, the cumulative risk of ipsilateral stroke/TIA
was 17% at 5 years in patients who were positive for
MES, as compared with 9% at 5 years in asymptomatic
patients who were MES negative ( p¼ 0.6).37
The latter study, however, illustrated a number of
important logistical issues regarding the potential
role of TCD for identifying high risk carotid steno-
ses in asymptomatic patients. Firstly, 11% of patients
had an inadequate temporal acoustic window and
2% of completed studies were technically inade-
quate. A further 5% of studies were not carried
out for the planned 60 minutes, presumably due to
technical difficulties or problems with the procedureEur J Vasc Endovasc Surg Vol 35, January 2008for the patient or technician. The rate of MES is low
in asymptomatic patients (0.16 MES per hour of study)
implying that extended examinations are required.37
Work continues on developing an ambulatory probe
with automated MES monitoring which would signif-
icantly enhance the utility of this technique.38,39
Other imaging techniques such as angiography, ther-
mography and intra-vascular ultrasound have been
demonstrated to identify some features of unstable pla-
ques, but since these methods are generally invasive,
they are not likely to be useful in assessing asymptom-
atic carotid atherosclerosis in the majority of patients.
Biological Markers of High Risk Carotid
Atherosclerosis
Inflammation, proteolysis, lipid accumulation, infec-
tion and thrombosis are all processes that have been
associated with atherosclerotic plaque instability and
secondary clinical events.12,13,19 With growing aware-
ness that stenosis severity (alone) is a poor guide as to
which sites of atherosclerosis should be treated, there
has been increasing interest in utilising biological
markers of plaque instability to more effectively target
interventions, especially in the asymptomatic patient.
Methods of targeting a variety of biological relevant
molecules using scintigraphic imaging have been de-
veloped.40 Targeted molecules include oxidized LDL,
annexin A5, deoxyglucose and metalloproteinases
(MMP).40 Ex vivo and limited in vivo studies have
demonstrated the potential of single photon emission
computed tomography (SPECT) and positron emis-
sion tomography (PET) in identifying some of these
molecules, however, the value of this type of imaging
in selecting high risk plaques for intervention remains
unclear.40,41
Elevated circulating concentrations of a rangeof pro-
teins have been related to atherosclerosis.42 A number
of studies have correlated plasma biomarkers in pa-
tients presenting with symptomatic and asymptomatic
carotid stenoses. Circulating biomarkers that have been
found to have elevated concentrations in symptomatic
patients in at least one study include; MMP-2, MMP-9,
sICAM-1, osteoprotegerin, fibrinogen, homocysteine
and anti chylamydia pneumoniae antibodies.43e48
However, cross-sectional studies are difficult to in-
terpret, because the elevated levels of biomarkers could
be a response to the stroke or TIA rather than being as-
sociatedwith primary plaque instability. Moreover, it is
very difficult to reliably match patient subgroups for
factors suchas ageandothercardiovascular risk factors.
Most prospective studies examining the relation-
ship between baseline circulating biomarker
7High Risk Carotid Plaqueconcentrations and subsequent stroke have been per-
formed in patients without documenting or stratify-
ing for the degree of carotid artery stenosis.49e51 In
the Framingham study of healthy elderly subjects,
baseline CRP in the top quartile predicted a 2 and
3-fold increased risk of stroke in men and women
respectively during a 12 year follow-up of 1462 sub-
jects.49 In a similar study of healthy 70e79 years old
subjects, increased baseline circulating IL-6 concentra-
tions (one standard deviation) predicted a 1.3-fold in-
crease in stroke during a 4 year follow-up after
adjusting for other risk factors.50 In a similar prospec-
tive study, lipoprotein-associated phospholipase A2
(Lp-PLA2) was also associated with a higher risk of
late stroke.51 More recently, Eldrup and colleagues
examined the relationship between plasma MMP-9
concentrations and the cumulative risk of stroke or
cardiovascular death.52 Patients studied included
both symptomatic (56%) and asymptomatic (44%)
subjects with 50% carotid stenosis in which carotid
intervention was not planned. Over a mean follow-
up of 4.4 years, plasma MMP-9 predicted combined
stroke and cardiovascular death, particularly when
combined with plaque echolucency.52
For biomarkers to be useful in selecting high risk
plaques in a population with an overall level of risk
that is low for stroke, a number of important criteria
are required. Firstly, the biomarker needs to be highly
specific and sensitive for predicting stroke as deter-
mined by receiver operator curves. Secondly, these
findings need to be tested prospectively in carefully
defined patient subgroups eg asymptomatic patients.
Thirdly, it has to be demonstrated that any ‘high
risk’ subgroup with high levels of circulating bio-
markers should benefit from interventions such as ca-
rotid surgery or stenting. It should be borne in mind
that elevated biomarkers may simply be predicting
the risk of ischaemic stroke as a result of its release
from multiple sites of atherosclerosis.
Conclusions
Overall, the best predictor of ‘high risk for stroke’
carotid atherosclerosis remains whether or not the
patient presented with symptoms (stroke/TIA). The
main challenge (for the future) remains the identifica-
tion of a subgroup of asymptomatic patients who will
benefit from angioplasty or surgery. A number of
techniques hold promise (high resolution MR, GSM,
scintigraphic imaging, TCD and plasma biomarkers)
but none have proved reliable enough to be introduced
into practice. Since the mechanisms underlying ischae-
mic stroke are multi-factorial and atherosclerosis isa systemic disease, it remains a distinct possibility
that carotid intervention in such a high risk group
may only afford the same absolute risk reduction as
that observed within the low risk group.
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